CN107709326B - 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶 - Google Patents

降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶 Download PDF

Info

Publication number
CN107709326B
CN107709326B CN201680017456.6A CN201680017456A CN107709326B CN 107709326 B CN107709326 B CN 107709326B CN 201680017456 A CN201680017456 A CN 201680017456A CN 107709326 B CN107709326 B CN 107709326B
Authority
CN
China
Prior art keywords
disease
mammal
alzheimer
tau
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680017456.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN107709326A (zh
Inventor
V·约翰
D·E·布雷德森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Buck Institute for Research on Aging
Original Assignee
Buck Institute for Research on Aging
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Buck Institute for Research on Aging filed Critical Buck Institute for Research on Aging
Publication of CN107709326A publication Critical patent/CN107709326A/zh
Application granted granted Critical
Publication of CN107709326B publication Critical patent/CN107709326B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680017456.6A 2015-02-18 2016-02-17 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶 Active CN107709326B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562117888P 2015-02-18 2015-02-18
US62/117,888 2015-02-18
PCT/US2016/018305 WO2016134042A2 (en) 2015-02-18 2016-02-17 Triazolopyridines and triazolopyrimidines that lower stress-induced p-tau

Publications (2)

Publication Number Publication Date
CN107709326A CN107709326A (zh) 2018-02-16
CN107709326B true CN107709326B (zh) 2021-12-17

Family

ID=56692299

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680017456.6A Active CN107709326B (zh) 2015-02-18 2016-02-17 降低应激诱导的p-tau的三唑并吡啶和三唑并嘧啶

Country Status (8)

Country Link
US (2) US10618899B2 (https=)
EP (1) EP3259274B1 (https=)
JP (1) JP6830895B2 (https=)
KR (1) KR102220260B1 (https=)
CN (1) CN107709326B (https=)
AU (1) AU2016220049C1 (https=)
CA (1) CA2976258C (https=)
WO (1) WO2016134042A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
EP3969639B1 (en) 2019-05-13 2025-03-12 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
ES2932481B2 (es) * 2021-07-09 2023-09-11 Consejo Superior Investigacion Compuestos inhibidores de la quinasa de tau y tubulina (ttbk)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1230184A (zh) * 1996-03-27 1999-09-29 杜邦药品公司 芳氨基稠合的吡啶和嘧啶
US6107301A (en) * 1993-10-12 2000-08-22 Dupont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1012151B1 (en) * 1997-09-02 2002-08-07 Bristol-Myers Squibb Pharma Company Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (crh) antagonists, useful for treating cns and stress-related disorders
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
JP6250394B2 (ja) 2010-08-19 2017-12-20 バック・インスティテュート・フォー・リサーチ・オン・エイジング 軽度の認知障害（ｍｃｉ）および関連障害の処置方法
US11325904B2 (en) 2011-08-02 2022-05-10 Buck Institute For Research On Aging Tropinol esters and related compounds to promote normal processing of APP
WO2013026021A2 (en) 2011-08-18 2013-02-21 Buck Institute For Research On Aging Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
AU2013235422B2 (en) 2012-03-19 2016-12-15 Buck Institute For Research On Aging APP specific BACE inhibitors (ASBIs) and uses thereof
EP2903436B1 (en) * 2012-09-19 2019-07-17 The Trustees Of The University Of Pennsylvania Heterocyclic compounds and their use for the treatment of neurodegenerative tauopathies
US20140371283A1 (en) 2013-02-12 2014-12-18 Buck Institute For Research On Aging Hydantoins that modulate bace-mediated app processing
KR102220260B1 (ko) 2015-02-18 2021-02-25 버크 인스티튜트 포 리서치 온 에이징 스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107301A (en) * 1993-10-12 2000-08-22 Dupont Pharmaceuticals Company 1N-alkyl-N-arylpyrimidinamines and derivatives thereof
CN1230184A (zh) * 1996-03-27 1999-09-29 杜邦药品公司 芳氨基稠合的吡啶和嘧啶
EP1293213A1 (en) * 2000-02-14 2003-03-19 Japan Tobacco Inc. Preventives/remedies for postoperative stress

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Corticotrophin Releasing Hormone: Chemistry and Recent Developments;James Garner;《Australian Journal of Chemistry》;20040101;第57卷(第5期);393-407 *

Also Published As

Publication number Publication date
US20180346466A1 (en) 2018-12-06
AU2016220049A1 (en) 2017-08-24
EP3259274A4 (en) 2018-08-01
US10618899B2 (en) 2020-04-14
WO2016134042A2 (en) 2016-08-25
CA2976258A1 (en) 2016-08-25
EP3259274A2 (en) 2017-12-27
AU2016220049C1 (en) 2021-02-25
AU2016220049B2 (en) 2020-09-24
US10844071B2 (en) 2020-11-24
WO2016134042A3 (en) 2016-10-13
JP6830895B2 (ja) 2021-02-17
KR102220260B1 (ko) 2021-02-25
KR20170117185A (ko) 2017-10-20
EP3259274B1 (en) 2023-06-28
CN107709326A (zh) 2018-02-16
US20200190094A1 (en) 2020-06-18
CA2976258C (en) 2024-02-20
JP2018505899A (ja) 2018-03-01

Similar Documents

Publication Publication Date Title
US11091444B2 (en) Hydantoins that modulate BACE-mediated app processing
JP6482458B2 (ja) Ａｐｐ特異性のｂａｃｅ（ａｓｂｉ）およびその使用
US10844071B2 (en) Substituted [1,2,3]triazolo[4,5-d]pyrimidines that lower stress-induced p-tau

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant